Navigation Links
Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
Date:5/7/2009

WALTHAM, Mass., May 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will host a conference call and webcast on Thursday, May 14, 2009, at 4:30 p.m. EDT to review the Company's new business developments and first quarter financial results.

To access the live call, dial 877-397-0291 (domestic) or 719-325-4857 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI), is a genetics-focused personalized health company that develops preventative consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventative and therapeutic products. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. T cell immunity enhanced by timing of interleukin-7 therapy
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
6. Interleukin-12 indicates survival prospects for melanoma patients
7. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
9. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
10. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings to include fashion, ... hottest Korean cosmetics and fashion trends sweeping the nation. The decision to expand beyond ... the great offerings that allow Koreans everywhere to look their best every single day. ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a ... teach and share with the others. “Grandpa's Visit” is the creation of published author, ... that she is much like the character in her book. She shares, “Mr. Rice ...
(Date:9/25/2017)... CA (PRWEB) , ... September 25, 2017 , ... Azadian ... a full-time office in downtown Los Angeles, to service existing clients in the Western ... areas. , “We are seeing an ever-increasing amount of business demand west of the ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our Creative World: ... life and seeks answers in both Eastern and Western religious traditions and spirituality such ... in the mind of humankind for the past thousands of years and still are,” ...
(Date:9/24/2017)... Turks & Caicos Islands, BWI (PRWEB) , ... September 24, 2017 ... ... Islands, the #1 rated resort on TripAdvisor and one of Provo's premier boutique resorts, ... no reported structural damage to the resort after devastating Hurricanes Irma and more recently ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting at ... Rodman & Renshaw 19 th Annual Global Investment Conference ... p.m. Pacific time). The conference is being held at the ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
Breaking Medicine Technology: